Literature DB >> 22286213

Synthesis, characterization and antiproliferative activity on mesothelioma cell lines of bis(carboxylato)platinum(IV) complexes based on picoplatin.

Mauro Ravera1, Elisabetta Gabano, Ilaria Zanellato, Ilaria Bonarrigo, Esther Escribano, Virtudes Moreno, Mercè Font-Bardia, Teresa Calvet, Domenico Osella.   

Abstract

The synthesis and characterization of a series of picoplatin-based (picoplatin = [PtCl(2)(mpy)(NH(3))], mpy = 2-methylpyridine), Pt(iv) complexes with axial carboxylato ligands of increasing length are reported. The synthesis is based on the oxidation with hydrogen peroxide of picoplatin to give the cis,cis,trans-[PtCl(2)(mpy)(NH(3))(OH)(2)] intermediate and then its transformation into the dicarboxylato complexes cis,cis,trans-[PtCl(2)(mpy)(NH(3))(RCOO)(2)] (R = CH(3)(CH(2))(n), n = 0-4) with the corresponding anhydride. Pt(iv) complexes with n = 0-2 were selected to be tested on four malignant pleural mesothelioma (MPM) cell lines, on human mesothelial cells (HMC), and on the cisplatin-sensitive ovarian A2780 cell line along with cisplatin as a metallo-drug reference. In general, the longer the axial chain, the more cytotoxic and selective the Pt(IV) complex is. Pt(IV) analogs show good activity on the MPM cell lines, approaching or in some case bypassing that of cisplatin and represent quite promising drug candidates for the treatment of tumors whose chemoresistance is mainly based on glutathione overexpression, such as MPM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22286213     DOI: 10.1039/c2dt11874b

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  7 in total

Review 1.  Synthetic methods for the preparation of platinum anticancer complexes.

Authors:  Justin J Wilson; Stephen J Lippard
Journal:  Chem Rev       Date:  2013-11-27       Impact factor: 60.622

2.  Elusive Intermediates in the Breakdown Reactivity Patterns of Prodrug Platinum(IV) Complexes.

Authors:  Davide Corinti; Maria Elisa Crestoni; Simonetta Fornarini; Fortuna Ponte; Nino Russo; Emilia Sicilia; Elisabetta Gabano; Domenico Osella
Journal:  J Am Soc Mass Spectrom       Date:  2019-04-12       Impact factor: 3.109

3.  Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity.

Authors:  Jonathan C Barnes; Peter M Bruno; Hung V-T Nguyen; Longyan Liao; Jenny Liu; Michael T Hemann; Jeremiah A Johnson
Journal:  J Am Chem Soc       Date:  2016-09-14       Impact factor: 15.419

4.  Activation of Platinum(IV) Prodrugs By Motexafin Gadolinium as a Redox Mediator.

Authors:  Gregory Thiabaud; Rebecca McCall; Guangan He; Jonathan F Arambula; Zahid H Siddik; Jonathan L Sessler
Journal:  Angew Chem Int Ed Engl       Date:  2016-07-05       Impact factor: 15.336

5.  Oxidative Stress Induced by Pt(IV) Pro-drugs Based on the Cisplatin Scaffold and Indole Carboxylic Acids in Axial Position.

Authors:  Dina Tolan; Valentina Gandin; Liam Morrison; Ahmed El-Nahas; Cristina Marzano; Diego Montagner; Andrea Erxleben
Journal:  Sci Rep       Date:  2016-07-11       Impact factor: 4.379

6.  Platinum(iv) dihydroxido diazido N-(heterocyclic)imine complexes are potently photocytotoxic when irradiated with visible light.

Authors:  Evyenia Shaili; Luca Salassa; Julie A Woods; Guy Clarkson; Peter J Sadler; Nicola J Farrer
Journal:  Chem Sci       Date:  2019-08-08       Impact factor: 9.825

7.  Platinum(IV)-azido monocarboxylato complexes are photocytotoxic under irradiation with visible light.

Authors:  Evyenia Shaili; Marίa J Romero; Luca Salassa; Julie A Woods; Jennifer S Butler; Isolda Romero-Canelón; Guy Clarkson; Abraha Habtemariam; Peter J Sadler; Nicola J Farrer
Journal:  Dalton Trans       Date:  2021-08-04       Impact factor: 4.390

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.